KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Xenon Pharmaceuticals (XENE) over the last 12 years, with Q3 2025 value amounting to $79.2 million.

  • Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) rose 169.62% to $79.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.2 million, marking a year-over-year increase of 169.62%. This contributed to the annual value of $77.9 million for FY2024, which is 1645.36% up from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $79.2 million, which was up 169.62% from $79.0 million recorded in Q2 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $79.2 million during Q3 2025, and registered a low of $36.8 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $63.9 million, with a median of $65.9 million in 2023.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 5485.77% in 2022, then soared by 82.04% in 2023.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $43.6 million in 2021, then soared by 38.77% to $60.5 million in 2022, then rose by 10.48% to $66.9 million in 2023, then rose by 16.45% to $77.9 million in 2024, then grew by 1.74% to $79.2 million in 2025.
  • Its last three reported values are $79.2 million in Q3 2025, $79.0 million for Q2 2025, and $78.7 million during Q1 2025.